title: Reply to MR Romano et al.
authors.forename: J
authors.initials: J
authors.lastname: Smith
authors.forename: D
authors.initials: D
authors.lastname: Steel
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000601:surgery; D006801:Humans; D058449:Intravitreal Injections; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D011300:Preoperative Care; D014821:Vitrectomy / Q000379:methods*; D014823:Vitreous Hemorrhage / Q000517:prevention & control*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab